✦ LIBER ✦

A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas

✍ Scribed by Rajni Sinha; Jonathan L. Kaufman; Hanna Jean Khoury Jr.; Nassoma King; Pareen J. Shenoy; Carol Lewis; Kevin Bumpers; Amanda Hutchison-Rzepka; Mourad Tighiouart; Leonard T. Heffner; Mary Jo Lechowicz; Sagar Lonial; Christopher R. Flowers

Book ID: 112066985
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 839 KB
Volume: 118
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.26660

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A pilot study of epratuzumab and rituxim

A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma

✍ Ivana N. M. Micallef; Brad S. Kahl; Matthew J. Maurer; Ahmet Dogan; Stephen M. A 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 2 views

Combination of ibrutinib with rituximab,

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study

✍ Younes, Anas; Thieblemont, Catherine; Morschhauser, Franck; Flinn, Ian; Friedber 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 305 KB

Efficacy and toxicity of 2 schedules of

Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma : A randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA)

✍ Vincent Ribrag; Christian Gisselbrecht; Corinne Haioun; Gilles Salles; Jean-Bapt 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

Combined cyclophosphamide, vincristine,

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas : Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group

✍ Christina Nickenig; Martin Dreyling; Eva Hoster; Michael Pfreundschuh; Lorenz Tr 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB 👁 2 views

## Abstract ## BACKGROUND. In patients with advanced‐stage follicular lymphoma (FL) and mantle cell lymphoma (MCL), conventional chemotherapy remains a noncurative approach, and no major improvement in overall survival has been achieved in recent decades. ## METHODS. The German Low‐Grade Lymphom